Verona Pharma plc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Verona Pharma plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q3 2024.
  • Verona Pharma plc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $7.65M, a 50.7% increase year-over-year.
  • Verona Pharma plc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $32.1M, a 69.3% increase year-over-year.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2023 was $19M, a 34.6% increase from 2022.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2022 was $14.1M, a 44.5% decline from 2021.
  • Verona Pharma plc annual Share-based Payment Arrangement, Expense for 2021 was $25.4M, a 14.6% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $32.1M $7.65M +$2.58M +50.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $29.5M $15.6M +$10.5M +207% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $19M $4.26M -$32K -0.75% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $19M $4.57M +$65K +1.44% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $18.9M $5.08M +$2.26M +80.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $16.7M $5.07M +$2.02M +66.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $14.7M $4.29M +$542K +14.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $14.1M $4.5M +$318K +7.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $13.8M $2.82M -$2.12M -43% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $15.9M $3.05M -$4.4M -59% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $20.3M $3.75M -$5.1M -57.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $25.4M $4.19M -$8.69M -67.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-07
Q3 2021 $34.1M $4.94M -$1.55M -23.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $35.7M $7.45M +$6.5M +684% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $29.2M $8.85M +$6.98M +374% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $22.2M $12.9M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 $6.49M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $950K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.87M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.